Hostname: page-component-7dd5485656-gs9qr Total loading time: 0 Render date: 2025-11-02T18:56:40.990Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Infection by Vancomycin-Resistant Enterococcus on Survival and Resource Utilization for Patients With Leukemia

Published online by Cambridge University Press:  02 January 2015

Peter B. Bach ,
Sharp F. Malak ,
Joseph Jurcic ,
Sarah E. Gelfand ,
Janet Eagan ,
Claudia Little  and
Kent A. Sepkowitz
Peter B. Bach*
Affiliation:
Department of Epidemiology and Biostatistics, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York Department of Medicine, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Sharp F. Malak
Affiliation:
Department of Medicine, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Joseph Jurcic
Affiliation:
Department of Medicine, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Sarah E. Gelfand
Affiliation:
Department of Epidemiology and Biostatistics, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Janet Eagan
Affiliation:
Department of Medicine, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Claudia Little
Affiliation:
Leukemia Disease Management Team, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
Kent A. Sepkowitz
Affiliation:
Department of Medicine, The Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
*
The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 221, New York, NY 10021
Get access Rights & Permissions [Opens in a new window]

Abstract

We estimated the impact of vancomycin-resistant Enterococcus (VRE) infection on the outcomes of patients with leukemia in a case-control study. Compared with their matched controls (n = 45), cases (n = 23) had 22% greater total charges and shorter survival (P= .04). These findings substantiate the need for aggressive interventions to prevent VRE transmission.

Information

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 8 , August 2002 , pp. 471 - 474
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Edmond, M, Wallace, S, McClish, D, Pfaller, M, Jones, R, Wenzel, R. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239–244.Google Scholar
2.Maslak, P, Weiss, M, Jurcic, J, et al. High dose idarubicin (Hida) with high dose cytarabine (HiDac) as induction therapy for newly diagnosed patients with AML. Blood 1998;92(suppl):231a. Abstract.Google Scholar
3.Wakefield, DS, Pfaller, M, Ludke, RL, Wenzel, RP. Methods for estimating days of hospitalization due to nosocomial infections. Med Care 1992; 30:373–376.Google Scholar
4.Edmond, MB, Ober, JF, Dawson, JD, Weinbaum, DL, Wenzel, RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234–1239.Google Scholar
5.Freeman, J, Rosner, B, McGowan, J. Adverse effects of nosocomial infection. J Infect Dis 1979;140:732–740.Google Scholar
6.Wakefield, D, Helms, C, Massanari, R, Mori, M, Pfaller, M. Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. Am J Infect Control 1998;16:185–192.Google Scholar
7.Spengler, R, Greenough, W. Hospital costs and mortality attributed to nosocomial bacteremias. JAMA 1978;240:2455–2458.Google Scholar
8.Haley, R, Schaberg, D, Crossley, K, Von Allmen, S, McGowan, J. Extra charges and prolongation of stay attributable to nosocomial infections: a prospective interhospital comparison. Am J Med 1981;70:51–58.Google Scholar
9.Wilcox, M, Cunniffe, J, Trundle, C, Redpath, C. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996;34:23–30.Google Scholar